Cargando…

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma

Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck, Olaf, Paret, Claudia, Russo, Alexandra, Burhenne, Jürgen, Fresnais, Margaux, Steimel, Kevin, Seidmann, Larissa, Wagner, Daniel-Christoph, Vewinger, Nadine, Lehmann, Nadine, Sprang, Maximilian, Backes, Nora, Roth, Lea, Neu, Marie Astrid, Wingerter, Arthur, Henninger, Nicole, El Malki, Khalifa, Otto, Henrike, Alt, Francesca, Desuki, Alexander, Kindler, Thomas, Faber, Joerg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225940/ https://www.ncbi.nlm.nih.gov/pubmed/32224911 http://dx.doi.org/10.3390/cancers12040793

Ejemplares similares

Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor
por: Russo, Alexandra, et al.
Publicado: (2019)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
por: Wingerter, Arthur, et al.
Publicado: (2021)

HGG-03. THE GLYCOSPHINGOLIPIDS METABOLISM IS A NOVEL TARGET IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
por: Paret, Claudia, et al.
Publicado: (2021)

Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells
por: Lehmann, Nadine, et al.
Publicado: (2020)

Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1
por: Paret, Claudia, et al.
Publicado: (2021)

Benefits of Exercise Training for Children and Adolescents Undergoing Cancer Treatment: Results From the Randomized Controlled MUCKI Trial
por: Stössel, Sandra, et al.
Publicado: (2020)

IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients
por: Vewinger, Nadine, et al.
Publicado: (2019)

Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy
por: Paret, Claudia, et al.
Publicado: (2016)

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
por: Fischer, Jeannette, et al.
Publicado: (2017)

Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy
por: Paret, Claudia, et al.
Publicado: (2017)

Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL
por: Ziegler, Nicole, et al.
Publicado: (2023)

CpG-Islands as Markers for Liquid Biopsies of Cancer Patients
por: Sprang, Maximilian, et al.
Publicado: (2020)

Exercise reduces systemic immune inflammation index (SII) in childhood cancer patients
por: Winker, Matteo, et al.
Publicado: (2021)

cbpManager: a web application to streamline the integration of clinical and genomic data in cBioPortal to support the Molecular Tumor Board
por: Ustjanzew, Arsenij, et al.
Publicado: (2021)

Desorption Kinetics Evaluation for the Development of Validated Desorption Electrospray Ionization-Mass Spectrometric Assays for Drug Quantification in Tissue Sections
por: Fresnais, Margaux, et al.
Publicado: (2023)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Quantification of Biologically Active DNA Alkylation in Temozolomide-Exposed Glioblastoma Cell Lines by Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry: Method Development and Recommendations for Validation
por: Fresnais, Margaux, et al.
Publicado: (2023)

Development and Validation of an LC–MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus
por: Fresnais, Margaux, et al.
Publicado: (2020)

Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay
por: Fresnais, Margaux, et al.
Publicado: (2020)

Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2′-Deoxyguanosine Methylations in DNA
por: Fresnais, Margaux, et al.
Publicado: (2023)

Glucosylceramide Synthase Inhibitors Induce Ceramide Accumulation and Sensitize H3K27 Mutant Diffuse Midline Glioma to Irradiation
por: El Malki, Khalifa, et al.
Publicado: (2023)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma
por: Fresnais, Margaux, et al.
Publicado: (2021)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
por: Fujita, Haruka, et al.
Publicado: (2019)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021)

Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022)

Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices—A Practical Example
por: Fresnais, Margaux, et al.
Publicado: (2022)

Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives
por: Fresnais, Margaux, et al.
Publicado: (2021)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma
por: Mehta, Shwetal, et al.
Publicado: (2022)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020)

Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib
por: Hirano, Taizou, et al.
Publicado: (2018)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j38lugbmsfgmhhcq9rmam9b02g